33905-38-3

Upstream product

• 81499-32-3 N-(3-(benzyloxy)phenyl)acetamide 
• 190070-39-4 acetic acid-(3-benzyloxy-N-methyl-anilide) 
• 100-44-7 benzyl chloride 
• 621-42-1 meta-hydroxyacetanilide 
• 911626-95-4 N-(3-benzyloxyphenyl)formamide 
• 74-94-2 dimethylamine borane 
• 20012-63-9 o-(benzyloxy)aniline 
• 50-00-0 formaldehyd 
• 1484-26-0 3-(benzyloxy)aniline 

Downstream Products

• 190070-39-4 acetic acid-(3-benzyloxy-N-methyl-anilide) 
• 195432-92-9 (E)-2-[(3-Benzyloxy-phenyl)-methyl-amino]-but-2-enedioic acid dimethyl ester 
• 906375-51-7 (5S,8S,10R)-5-Cyclohexyl-2-methyl-3,6-dioxo-11,15-dioxa-2,4,7-triaza-tricyclo[14.3.1.1^7,10]henicosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-8-carboxylic acid 
• 906375-48-2 (5S,8S,10R)-5-Cyclohexyl-2-methyl-3,6-dioxo-11,15-dioxa-2,4,7-triaza-tricyclo[14.3.1.1^7,10]henicosa-1⁽¹⁹⁾,16⁽²⁰⁾,17-triene-8-carboxylic acid tert-butyl ester 
• 906375-45-9 (2S,4R)-1-{(S)-2-[3-(3-Benzyloxy-phenyl)-3-methyl-ureido]-2-cyclohexyl-acetyl}-4-(3-benzyloxy-propoxy)-pyrrolidine-2-carboxylic acid tert-butyl ester 
• 911626-96-5 (3-benzyloxy-phenyl)-methyl-carbamoyl chloride 
• 1259926-34-5 2,2-dimethylpropionic acid 2-{[3-benzyloxy-4-(2-thiophene-2-ylvinyl)-phenyl]methylamino}ethyl ester 
• 1259926-35-6 [3-benzyloxy-4-(2-thiophene-2-ylvinyl)-phenyl]-[2-(tert-butyldimethylsilanyloxy)ethyl]methylamine 
• 1259926-36-7 5-[2-(2-benzyloxy-4-{[2-(tert-butyldimethylsilanyloxy)-ethyl]methylamino}phenyl)vinyl]thiophene-2-carbaldehyde 
• 1259926-37-8 5-(2-{2-benzyloxy-4-[(2-hydroxyethyl)-methylamino]-phenyl}-vinyl)-thiophene-2-carbaldehyde 
• 1259926-38-9 2-(4-{2-[5-(2-{2-benzyloxy-4-[(2-hydroxyethyl)methylamino]phenyl}vinyl)thiophene-2-yl]vinyl}-3-cyano-5-phenyl-5-trifluoromethyl-5H-furan-2-ylidene)malononitrile 
• 875919-40-7 C₂₂H₃₁NO₂SSi 
• 1259926-42-5 5-(4-((2-hydroxyethyl)(methyl)amino)styryl)thiophene-2-carbaldehyde 
• 1259926-43-6 C₃₂H₂₃F₃N₄O₂S 

Relevant academic research and scientific papers

SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME

Problem to Be Solved: to provide a chromophore having a far superior nonlinear optical activity to conventional chromophores and to provide a nonlinear optical element comprising said chromophore. Solution: a chromophore comprising a donor structure D, a π-conjugated bridge structure B, and an acceptor structure A, the donor structure D comprising an aryl group substituted with a substituted oxy group; and a nonlinear optical element comprising said chromophore.

Nonlinear optical side-chain polymers post-functionalized with high-β chromophores exhibiting large electro-optic property

Electro-optic side-chain polymers have been synthesized by the post-functionalization of methacrylate isocyanate polymers with novel phenyl vinylene thiophene vinylene bridge (FTC) nonlinear optical chromophores. For this application, FTC-based chromophores were modified in their electronic donor structure, exhibiting much larger molecular hyperpolarizabilities compared with the benchmark FTC. Of these new chromophores, absorption spectra, hyper-Rayleigh scattering experiment, and thermal analysis were carried out to confirm availability as effective nonlinear optical units for electro-optic side-chain polymers. The electro-optic coefficients (r33) of obtained polymers were investigated in the process of in situ poling by monitoring the temperature, current flow, poling field, and electro-optic signal. Compared with the nonsubstituted analogue, benxyloxy modified FTC chromophore significantly achieved higher nonlinear optical property, exhibiting molecular hyperpolarizability at 1.9 μm of 4600 × 10-30 esu and an r33 value of 150 pm/V at the wavelength of 1.31 μm. Synthesized electro-optic polymers showed high glass transition temperature (Tg), so that the temporal stability examination exhibited >78% of the electro-optic intensity remaining at 85 °C over 500 h. Copyright

Phenyl and pyridyl LTA4H modulators

Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and inflammatory conditions.

Synthesis and pharmacological evaluation of new cysLT1 receptor antagonists

This paper describes the synthesis and pharmacological evaluation of three series of compounds 4a-b, 13a-k and 19, structurally related to the known potent cysLT1 receptor antagonists RG-12553, IC1-204219 and ONO-1078, respectively. The common structural feature of these new series is the presence of a 4-quinolone nucleus acting as a template for substitution of the aromatic nucleus present in the prototype antagonists. We describe the evolution of these series leading to antagonists with potency at nanomolar concentrations in vitro.